Cobalt Laboratories Inc., Sun Pharmaceuticals Industries Ltd., Teva, Actavis, Lupin, Mylan Pharmaceuticals Inc., Novartis, Pfizer, Wockhardt neurology news
The U.S. District Court for the District of Delaware ruled in favor of Pfizer in a 2009 patent infringement suit brought by Pfizer related to generic versions of its pain and seizure drug Lyrica pregabalin. The court ruled that U.S. Patent Nos. 6,197,819; 5,563,175; and RE 41,920 covering pregabalin and methods for using pregabalin to treat seizure disorders and pain are valid and that proposed generic products would infringe certain claims. The ruling enjoins Teva and other generic manufacturers, including Novartis' Sandoz generic unit and Mylan's Alphapharm Pty. Ltd. generics subsidiary, from manufacturing, using, offering for sale or selling generic versions of Lyrica until the '819 and '175 patents expire. The '819 patent expires in 2018 while the '175 patent expires in 2013. Pfizer licensed the '819 and '175 patents from Northwestern University ...